Vital Signs - Perspectives in Oncology Drug Delivery


Regular Price: USD 1,500.00

Special Price USD 1,050.00

30% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,050.00


Be the first to review this product

This issue of Vital Signs, released on January 18, 2010, provides a strategic overview of trends in MD, nurse and cancer patient feedback about drug delivery and treatment in oncology, as well as the value sought from this area from multiple facets of the pharma industry. Additionally, a company spotlight is provided for Cure DM, a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin therapy. Reimbursement and regulatory news from the FDA is also provided for the week of December 28, 2009.

Table of Contents

Vital Signs - Perspectives in Oncology Drug DeliveryVital Signs: 18 January 2010This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.